- Date2025-04-18
Publication of Review Result of the 2nd Serious Illness (Cancer)
Review Committee of 2025
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu) releases the result of the deliberations of the 2nd Cancer Review Committee in 2025 on ‘Reimbursement criteria for drugs used for cancer patients (Improvement of reimbursement standards reflection clinical reality)’ as follows.
○ New pharmaceutical (application for determination of health insurance coverage) and expansion of reimbursement standards
Category Product Pharmaceutical company Efficacy and effectiveness Deliberation results Application for healthcare Benefit Reimbursement Welireg Tab. (Belzutifan) MSD Korea Treatment of renal cell carcinoma, central nervous system (CNS) hemangioblastoma, pancreatic neuroendocrine tumor, which are not in need of an emergency surgery, for an adult patient contracting von Hippel- Lindau (VHL) To be discussed again Application for healthcare Benefit Reimbursement Ledaga Gel (Chlormethine Hydrochloride) Synex Topical treatment for an adult patient contracting early MF-Type CTCL who received prior skin-directed therapy Reimbursement criteria to be established Application for healthcare Benefit Reimbursement Omjjara Tab. (Momelotinib Hydrochloride Hydrate) GSK Treatment for an anaemic adult developing intermediate or highrisk myelofibrosis (primary myelofibrosis, myelofibrosis after polycythemia vera or essential thrombocythemia) Reimbursement criteria to be established Expand reimbursement scope Erleada Tab. (Apalutamide) Janssen Korea Treatment for a patient contracting high risk nmCRPC Reimbursement criteria to be established Expand reimbursement scope Calmtop Inj. (Irinotecan Hydrochloride) HK inno.N etc Esophageal cancer (off limit use) Reimbursement criteria to be established Expand reimbursement scope Enhertu Inj. (Trastuzumab deruxtecan) Daiichi Sankyo Korea Treatment of a patient contracting topically advanced or metastatic gastric or gastoesophageal junction cancer with HER2-positive, who received two or more therapies including prior HER2-targeted treatment Reimbursement criteria to be established (Clarification of previous treatment methods)
